Deep Track Capital LP Invests $15.32 Million in Immunocore Holdings plc (NASDAQ:IMCR)

Deep Track Capital LP bought a new stake in Immunocore Holdings plc (NASDAQ:IMCR - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 519,376 shares of the company's stock, valued at approximately $15,322,000. Deep Track Capital LP owned 1.04% of Immunocore as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Crestline Management LP purchased a new stake in shares of Immunocore during the 4th quarter valued at $736,000. Cubist Systematic Strategies LLC acquired a new position in Immunocore in the fourth quarter valued at $3,145,000. BNP Paribas Financial Markets purchased a new stake in Immunocore during the fourth quarter valued at about $5,697,000. The Manufacturers Life Insurance Company increased its stake in Immunocore by 6.3% during the fourth quarter. The Manufacturers Life Insurance Company now owns 114,151 shares of the company's stock worth $3,367,000 after acquiring an additional 6,760 shares during the last quarter. Finally, Virtus ETF Advisers LLC raised its holdings in shares of Immunocore by 39.0% in the 4th quarter. Virtus ETF Advisers LLC now owns 11,536 shares of the company's stock worth $340,000 after purchasing an additional 3,238 shares during the period. Institutional investors and hedge funds own 84.50% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the stock. Needham & Company LLC reissued a "buy" rating and set a $71.00 target price on shares of Immunocore in a research report on Thursday, April 10th. Mizuho dropped their price objective on shares of Immunocore from $38.00 to $33.00 and set a "neutral" rating for the company in a research report on Monday, April 7th. JPMorgan Chase & Co. reduced their target price on shares of Immunocore from $54.00 to $50.00 and set an "overweight" rating on the stock in a report on Monday, April 14th. HC Wainwright reiterated a "buy" rating and issued a $100.00 price target on shares of Immunocore in a report on Wednesday, March 12th. Finally, Morgan Stanley restated an "equal weight" rating and set a $35.00 price objective on shares of Immunocore in a research note on Friday, March 7th. One analyst has rated the stock with a sell rating, four have issued a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $59.44.

Immunocore Stock Down 8.4 %

Shares of Immunocore stock opened at $28.06 on Wednesday. Immunocore Holdings plc has a 1-year low of $23.15 and a 1-year high of $62.22. The company has a market capitalization of $1.40 billion, a PE ratio of -29.54 and a beta of 0.75. The company has a debt-to-equity ratio of 1.03, a current ratio of 3.78 and a quick ratio of 3.76. The business has a 50-day moving average of $28.80 and a 200-day moving average of $30.23.

Insider Activity at Immunocore

In related news, Director Bros. Advisors Lp Baker purchased 807,338 shares of the business's stock in a transaction that occurred on Monday, March 17th. The shares were purchased at an average cost of $29.72 per share, with a total value of $23,994,085.36. Following the completion of the acquisition, the director now directly owns 2,144,060 shares of the company's stock, valued at approximately $63,721,463.20. The trade was a 60.40 % increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 10.40% of the stock is currently owned by company insiders.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.